Discovery of neddylation E2s inhibitors with therapeutic activity

Neddylation is the writing of monomers or polymers of neural precursor cells expressed developmentally down-regulated 8 (NEDD8) to substrate. For neddylation to occur, three enzymes are required: activators (E1), conjugators (E2), and ligators (E3). However, the central role is played by the ubiquitin-conjugating enzymes E2M (UBE2M) and E2F (UBE2F), which are part of the E2 enzyme family. Recent understanding of the structure and mechanism of these two proteins provides insight into their physiological effects on apoptosis, cell cycle arrest and genome stability. To treat cancer, it is therefore appealing to develop novel inhibitors against UBE2M or UBE2F interactions with either E1 or E3. In this evaluation, we summarized the existing understanding of E2 interaction with E1 and E3 and reviewed the prospective of using neddylation E2 as a pharmacological target for evolving new anti-cancer remedies.

Automated summary

Neddylation is a process that involves adding NEDD8, a protein, to other molecules in neural precursor cells. This process requires three enzymes: activators (E1), conjugators (E2), and ligators (E3). Recent research has highlighted the importance of two specific enzymes, UBE2M and UBE2F, in neddylation and their potential as targets for developing anti-cancer therapies. This evaluation summarizes the current understanding of the interaction between E2 and E1 or E3, and explores the prospects of using neddylation E2 as a pharmacological target for cancer treatment.